ClinicalTrials.gg
CompletedNCT07026500Updated Jun 18, 2025

Clinical Trial for Batch Consistency of EV71 Vaccine

A Phase 4 interventional study of EV71 Vaccine in EV71 Vaccine, sponsored by Sinovac Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 6 Months to 35 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-18.

Sponsored by Sinovac Biotech Co., Ltd · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Registered 5 years 8 months after the study started (first participant enrolled Sep 2019, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
6 Months to 35 Months
Sex
All
01

Study summary

This trial is designed as a single-center, randomized, double-blind study. A total of 720 infants aged 6 to 35 months are selected (with 240 subjects in each age group: 6-11 months, 12-23 months, and 24-35 months). Subjects from different age groups are randomly allocated to three batch groups in a 1:1:1 ratio, and receive two doses of the EV71 vaccine from the commercial production batch on days 0 and 30. After each vaccination dose, subjects will be observed for immediate reactions for 30 minutes and for solicited adverse events for the next 7 days, as well as for unsolicited adverse events over the 30 days following vaccination. All subjects will have blood samples collected on day 0 (pre-immunization) and day 60 for serum antibody testing. Additionally, 270 subjects will be selected, for additional blood sampling at various time points: 7 days, 14 days, and 30 days after the first dose, and 7 days and 14 days after the second dose, to assess the EV71 antibody levels at different timepoints following various doses of vaccination.

02

Conditions studied

  • EV71 Vaccine
03

In context

Lead sponsor

Sinovac Biotech Co., Ltd is the lead sponsor of 93 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 35 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants and young children aged 6 to 35 months.
  • Able to provide legal identification.
  • The guardian of the subject has the ability to understand and agrees to sign the form.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with the EV71 vaccine.
  • History of hand, foot, and mouth disease.
  • History of allergies, asthma, including allergies to vaccines or vaccine components, and severe adverse reactions to vaccines, such as urticaria, difficulty breathing, angioedema, or abdominal pain.
  • Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
  • diseases or immune deficiencies/.
  • Severe neurological disorders (epilepsy, convulsions, or seizures) or mental illness.
  • History of thyroidectomy, asplenia, functional asplenia, or any condition leading to asplenia or splenectomy.
  • Blood coagulation abnormalities diagnosed by a physician (such as clotting factor deficiencies, coagulopathies, abnormalities) or evident bruising or bleeding disorders.
  • Treatment with immunosuppressants, cytotoxic therapy, or inhaled within 6 months prior to enrollment (excluding corticosteroid nasal spray therapy for allergic rhinitis, or topical corticosteroid treatment for acute non-complicated dermatitis).
  • Receipt of blood products within 3 months prior to vaccination with the trial vaccine.
  • Receipt of other vaccines within 30 days prior to vaccination with the trial vaccine.
  • Receipt of within 14 days prior to vaccination with the trial vaccine.
  • Receipt of subunit or inactivated vaccines within 7 days prior to vaccination with the trial vaccine.
  • Any acute illness or acute exacerbation of chronic illness within the past 7 days.
  • Fever before receiving the investigational vaccine, with an axillary temperature > 37.0°C.
  • Any other factors that, in the investigator's judgment, make the subject unsuitable for participation in the clinical trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
720 participants (actual)

Study arms

  • Experimental
    Batch group 1

    EV71 vaccine first commercial production batch

    Biological: EV71 Vaccine

  • Experimental
    Batch group 2

    EV71 vaccine second commercial production batch

    Biological: EV71 Vaccine

  • Experimental
    Batch group 3

    EV71 vaccine third commercial production batch

    Biological: EV71 Vaccine

Interventions

  • BiologicalEV71 Vaccine

    EV71 vaccine of commercial production batch

06

What researchers measure

Primary outcomes

  1. The GMT of EV71 neutralizing antibodies 30 days after complete immunization with the EV71 vaccine

    Time frame: 30 days after second dose

Secondary outcomes

  1. Seroconversion rates, seropositive rates, and GMT of antibodies at 7 days, 14 days, and 30 days after the first dose of the EV71 vaccine

    Time frame: 7,14 and 30 days after the first dose

  2. Seroconversion rates, seropositive rates, and GMT of antibodies at 7 days and 14 days after the second dose of the EV71 vaccine, as well as the seroconversion rate and seropositive rate at 30 days post-vaccination

    Time frame: 7,14 and 30 days after the second dose

  3. The incidence of adverse reactions within 30 days after each dose of the EV71 vaccine

    Time frame: 30 days after each dose

  4. The incidence of solicited adverse events within 0-7 days after each dose of the EV71 vaccine

    Time frame: 7 days after each dose

  5. The incidence of serious adverse events during the safety observation period

    Time frame: 30 days after the second dose

07

Study locations

1 site
  • Dazhu County Center for Disease Control and Prevention
    Dazhu, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Apr 2020, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2025
First posted
Jun 18, 2025
StartActual
Sep 19, 2019
Primary completionActual
Apr 30, 2020
CompletionActual
May 31, 2020
Last update
Jun 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07026500
Responsible party
Sponsor
First posted
Jun 18, 2025
Start date
Sep 19, 2019
Primary completion
Apr 30, 2020
Completion
May 31, 2020
Last update
Jun 18, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enterovirus 71 vaccine

Start the discussion